Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.

Saved in:
Bibliographic Details
Title: Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.
Authors: Yimer H; Texas Oncology, Tyler/US Oncology Research, Tyler, TX, USA., Melear J; Texas Oncology, Austin, TX, USA., Faber E; Oncology Hematology Care, Inc, Cincinnati, OH, USA., Bensinger WI; Swedish Cancer Institute, Seattle, WA, USA., Burke JM; US Oncology Research, Rocky Mountain Cancer Centers, Aurora, CO, USA., Narang M; US Oncology Research, Maryland Oncology Hematology, Columbia, MD, USA., Stevens D; Norton Health Care, Louisville, KY, USA., Gray KS; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Lutska Y; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Bobba P; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Qi K; Janssen Research & Development, LLC, Titusville, NJ, USA., Hoehn D; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Qi M; Janssen Research & Development, LLC, Spring House, PA, USA., Lin TS; Janssen Scientific Affairs, LLC, Horsham, PA, USA., Rifkin RM; US Oncology Research, Rocky Mountain Cancer Centers, Denver, CO, USA.
Source: Leukemia & lymphoma [Leuk Lymphoma] 2022 Oct; Vol. 63 (10), pp. 2383-2392. Date of Electronic Publication: 2022 Jun 22.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1029-2403
DOI:10.1080/10428194.2022.2076847